A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. [electronic resource]
Producer: 20070105Description: 69-77 p. digitalISSN:- 0169-5002
- Adult
- Aged
- Animals
- Antibodies, Monoclonal -- adverse effects
- Antineoplastic Agents, Phytogenic -- adverse effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Docetaxel
- Female
- Humans
- Immunoconjugates -- adverse effects
- Lung Neoplasms -- drug therapy
- Male
- Mice
- Middle Aged
- Quality of Life
- Survival Rate
- Taxoids -- adverse effects
- Treatment Outcome
- United States
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.